INKT

MKT CAP:$54M

MiNK Therapeutics, Inc.

Market Cap

$54M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$10.73-$0.39 (-3.51%)

Apr 23, 2026

Company Details

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...

CEO

Jennifer S. Buell

IPO Date

Oct 15, 2021

Website

minktherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$12M

EPS (Diluted)

-$3.06

Free Cash Flow

-$1.3B

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 13, 2026

PENDING

Q3 2025

Nov 14, 2025

$0EPS -$0.65

Q2 2025

Aug 14, 2025

$0EPS -$1.06

Q1 2025

May 15, 2025

$0EPS -$0.70

FY 2024

Mar 18, 2025

$0EPS -$2.80

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	-$23.8K	-$6M
Q1 22	$0	-$27.1K	-$7M
Q2 22	$0	-$28.3K	-$8M
Q3 22	$0	-$28.4K	-$8M
Q4 22	$0	-$37.9K	-$8M
Q1 23	$0	-$45.7K	-$6M
Q2 23	$0	-$51.9K	-$6M
Q3 23	$0	-$53.5K	-$5M
Q4 23	$0	-$53.6K	-$6M
Q1 24	$0	-$53.8K	-$4M
Q2 24	$0	-$45.1K	-$3M
Q3 24	$0	-$62.6K	-$2M
Q4 24	$0	-$53.9K	-$2M
Q1 25	$0	-$50.8K	-$3M
Q2 25	$0	-$48.8K	-$4M
Q3 25	$0	-$43.7K	-$3M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$2M	-$2M
Q1 22	-$4M	-$4M
Q2 22	-$5M	-$5M
Q3 22	-$6M	-$6M
Q4 22	-$4M	-$5M
Q1 23	-$4M	-$4M
Q2 23	-$4M	-$4M
Q3 23	-$4M	-$4M
Q4 23	-$3M	-$3M
Q1 24	-$3M	-$3M
Q2 24	-$2M	-$2M
Q3 24	-$3M	-$3M
Q4 24	-$2M	-$2M
Q1 25	-$1.3B	-$1.3B
Q2 25	-$2M	-$2M
Q3 25	-$941.3K	-$941.4K

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$5
Q2 22	$62.4K
Q3 22	$59.8K
Q4 22	$127.8K
Q1 23	$13.5K
Q2 23	$37.0K
Q3 23	$23.0K
Q4 23	$0
Q1 24	$3
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+314.1%
Q1 22	—	+99.7%
Q2 22	—	+37.2%
Q3 22	—	+92.5%
Q4 22	—	+25.0%
Q1 23	—	-20.6%
Q2 23	—	-17.6%
Q3 23	—	-34.6%
Q4 23	—	-30.3%
Q1 24	—	-34.6%
Q2 24	—	-54.3%
Q3 24	—	-67.4%
Q4 24	—	-59.7%
Q1 25	—	-33.9%
Q2 25	—	+27.1%
Q3 25	—	+75.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$667.0K	—
Q1 22	$785.5K	—
Q2 22	$800.8K	—
Q3 22	$772.9K	—
Q4 22	$0	—
Q1 23	$921.1K	—
Q2 23	$898.3K	—
Q3 23	$939.3K	—
Q4 23	$1M	—
Q1 24	$592.0K	—
Q2 24	$436.9K	—
Q3 24	$883.0K	—
Q4 24	$390.0K	—
Q1 25	$591.1K	—
Q2 25	$896.6K	—
Q3 25	$620.6K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 21	$4M	—	$2M
Q1 22	$5M	—	$2M
Q2 22	$6M	—	$2M
Q3 22	$6M	—	$2M
Q4 22	$6M	—	$2M
Q1 23	$4M	—	$2M
Q2 23	$5M	—	$2M
Q3 23	$3M	—	$2M
Q4 23	$3M	—	$2M
Q1 24	$3M	—	$1M
Q2 24	$2M	—	$1M
Q3 24	$540.6K	—	$1M
Q4 24	$1M	—	$755.1K
Q1 25	$1M	—	$1M
Q2 25	$2M	$2M	—
Q3 25	$1M	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$39M	$0	$39M
Q1 22	$35M	$0	$35M
Q2 22	$30M	$0	$30M
Q3 22	$24M	$0	$24M
Q4 22	$20M	$0	$20M
Q1 23	$15M	$0	$15M
Q2 23	$11M	$0	$11M
Q3 23	$6M	$0	$6M
Q4 23	$3M	$0	$3M
Q1 24	$6M	$0	$6M
Q2 24	$9M	$0	$9M
Q3 24	$6M	$0	$6M
Q4 24	$5M	$0	$5M
Q1 25	$3M	$0	$3M
Q2 25	$2M	$0	$2M
Q3 25	$14M	$0	$14M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	3M	0.0%	+15.7%
Q1 22	3M	+2.0%	+18.0%
Q2 22	3M	+0.3%	+18.4%
Q3 22	3M	+0.4%	+2.7%
Q4 22	3M	+0.1%	+2.9%
Q1 23	3M	+0.5%	+1.4%
Q2 23	3M	+1.3%	+2.3%
Q3 23	3M	+0.3%	+2.2%
Q4 23	3M	+0.2%	+2.2%
Q1 24	3M	+0.2%	+2.0%
Q2 24	4M	+7.2%	+7.9%
Q3 24	4M	+6.4%	+14.6%
Q4 24	4M	-4.6%	+9.2%
Q1 25	4M	+5.1%	+14.5%
Q2 25	4M	+0.4%	+7.2%
Q3 25	4M	+11.6%	+12.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	33
Q1 22	$0	33
Q2 22	$0	33
Q3 22	$0	33
Q4 22	$0	37
Q1 23	$0	37
Q2 23	$0	37
Q3 23	$0	37
Q4 23	$0	31
Q1 24	$0	31
Q2 24	$0	31
Q3 24	$0	31
Q4 24	$0	23
Q1 25	$0	23
Q2 25	$0	23
Q3 25	$0	23

Revenue / Employee